Holen Sie sich die Stockscreener-App
10.82
8.20%
0.82
Handel nachbörslich:
10.36
-0.46
-4.25%
Schlusskurs vom Vortag:
$10.00
Offen:
$10.18
24-Stunden-Volumen:
2.47M
Relative Volume:
1.50
Marktkapitalisierung:
$3.40B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-15.90
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+2.56%
1M Leistung:
+8.09%
6M Leistung:
+41.25%
1J Leistung:
+27.74%
1-Tages-Spanne:
$10.06
$10.97
1-Wochen-Bereich:
$9.99
$10.97
52-Wochen-Spanne:
$6.685
$10.97
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
10.82 | 3.14B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Piper Sandler Reaffirms Overweight Rating for Amneal Pharmaceuticals (NASDAQ:AMRX) - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Option Care Health (OPCH) and Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal raises 2025 EPS guidance and outlines $300M–$500M CREXONT sales target as portfolio expansion accelerates - MSN
Amneal Pharmaceuticals stock hits 52-week high at $10.72 By Investing.com - Investing.com Australia
Does Amneal Pharmaceuticals Inc. show high probability of reboundWeekly Profit Analysis & Community Supported Trade Ideas - newser.com
Amneal Pharmaceuticals Hits New 52-Week High of $10.70 - Markets Mojo
Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Why Amneal (AMRX) Stock Is Up Today - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High on Strong Earnings - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $10.72 - Investing.com
Truist Raises Price Target on Amneal Pharmaceuticals to $14 From $13, Keeps Buy Rating - MarketScreener
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance - MarketBeat
Will Amneal Pharmaceuticals Inc. stock benefit from automationGap Up & Weekly Chart Analysis and Trade Guides - newser.com
What analyst consensus says on Amneal Pharmaceuticals Inc. stockRate Cut & Safe Capital Growth Stock Tips - newser.com
How high can Amneal Pharmaceuticals Inc. stock goEarnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakoutWeekly Risk Report & Growth-Oriented Investment Plans - newser.com
Published on: 2025-10-31 02:59:36 - newser.com
Amneal Pharmaceuticals (AMRX) Profitability Milestone Tests Investor Optimism on Growth and Valuation - Yahoo Finance
Amneal Pharmaceuticals Reports Strong Q3 2025 Results - TipRanks
Published on: 2025-10-31 00:29:31 - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum play2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Amneal Q3 2025 slides: Revenue up 12% as specialty products gain traction - Investing.com Canada
Amneal: Q3 Earnings Snapshot - Norwalk Hour
How Amneal Pharmaceuticals’ (AMRX) Return to Profitability and Respiratory Product Wins Have Changed Its Investment Story - simplywall.st
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Earnings call transcript: Amneal Pharma Q3 2025 beats EPS forecast, stock rises - Investing.com
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Amneal Pharmaceuticals, Inc. (AMRX) Q3 FY2025 earnings call transcript - Yahoo Finance
Amneal Pharmaceuticals Outperforms Expectations And Raises Its Full-Year Outlook - Finimize
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Amneal Pharmaceuticals Q3 Adjusted Earnings, Revenue Rise; 2025 EPS Outlook Raised - MarketScreener
Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars - The Globe and Mail
Amneal Pharmaceuticals' Q3 revenue beats estimates, raises guidance for adjusted EBITDA - MarketScreener
(AMRX) Amneal Pharmaceuticals Expects Full Year 2025 Adjusted EPS Range $0.75$0.80, vs. FactSet Est of $0.76 - MarketScreener
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q3 Revenue $784.5M, vs. FactSet Est of $773.9M - MarketScreener
Amneal Pharmaceuticals rise nearly 7% as Q3 results beat expectations By Investing.com - Investing.com Canada
Amneal Reports Third Quarter 2025 Financial Results - The Manila Times
AlphaQuest LLC Acquires 49,305 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX - MarketBeat
Is Amneal Pharmaceuticals Inc. stock resilient to inflationJuly 2025 Highlights & AI Driven Price Predictions - newser.com
Amneal Gets Tentative FDA Approval for Asthma Treatment - MarketScreener
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol - The Manila Times
Amneal (AMRX) receives FDA tentative approval for generic QVAR inhaler; first MDI product - Stock Titan
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Steady Share Price Gains and Growth Initiatives - Yahoo Finance
Will Amneal Pharmaceuticals Inc. stock reach Wall Street targetsWeekly Investment Recap & Reliable Breakout Forecasts - newser.com
Amneal Earnings: What To Look For From AMRX - Barchart.com
Brekiya Migraine Autoinjector Launch Could Be a Game Changer for Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX) and Novan (NOVN) - The Globe and Mail
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.18%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):